The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001).
 
Grainne M. O'Kane
Honoraria - AstraZeneca; Incyte; MSD Oncology; Roche; Servier/Pfizer
Consulting or Advisory Role - AstraZeneca Canada; Incyte; Roche; Servier
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - MSD
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Jennifer Spratlin
Honoraria - Celgene; Eisai; Lilly/ImClone; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Celgene; Eisai; Lilly/ImClone; Sanofi; Taiho Pharmaceutical
Research Funding - Celgene (Inst); Sanofi
 
Sun Young Rha
Consulting or Advisory Role - Aadi; Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; Eutilex; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks
 
Elena Elimova
Employment - Merck (I)
Honoraria - Roche Canada
Consulting or Advisory Role - Abbvie; Adaptimmune (Inst); Astellas Pharma; BeiGene (Inst); Bristol-Myers Squibb (Inst); Signatera; Viracta Therapeutics; Zymeworks (Inst)
Research Funding - Arcus Biosciences (Inst); AstraZeneca Canada (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst); Zymeworks (Inst)
 
Petr Kavan
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Merck; Novartis; Pfizer; Roche Canada; Taiho Pharmaceutical
 
Rachel Anne Goodwin
Honoraria - Advanced Accelerator Applications; Eisai; Incyte; Incyte; Ipsen; Merck; Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Amgen; Apobiologix; Astellas Pharma; AstraZeneca Canada; Bayer; Eisai; Incyte; Ipsen; Merck; MSD; Novartis; Pfizer; Roche Canada; Taiho Pharmaceutical; Viatris
Speakers' Bureau - Amgen; Bayer; Bayer; Eisai; Ipsen; Merck; Mylan; Pfizer
Research Funding - Eisai; Ipsen
Travel, Accommodations, Expenses - Ipsen; Novartis; Pfizer
 
Yongjun Cha
Honoraria - Merck; MSD Oncology; Roche
Consulting or Advisory Role - CellabMED, Inc.; IMBdx
Speakers' Bureau - MSD
Expert Testimony - GC Biopharma; Ono Pharmaceutical
 
Seung Tae Kim
No Relationships to Disclose
 
E. Russell McAllister
Employment - Bold Therapeutics
Leadership - Bold Therapeutics
Stock and Other Ownership Interests - Bold Therapeutics
Patents, Royalties, Other Intellectual Property - Bold Therapeutics
 
Michelle Jones
Employment - Bold Therapeutics
Stock and Other Ownership Interests - Bold Therapeutics
 
Malcolm Snow
Employment - Bold Therapeutics
Stock and Other Ownership Interests - Bold Therapeutics
 
Yasmin Lemmerick
No Relationships to Disclose
 
Gonzalo Spera
No Relationships to Disclose
 
Jim Pankovich
Employment - Bold Therapeutics
Leadership - Bold Therapeutics
Stock and Other Ownership Interests - Bold Therapeutics
Patents, Royalties, Other Intellectual Property - Bold Therapeutics Inc. patents